United States Clinical Trials Report — June 2026

As June 2026 unfolds, patients and healthy volunteers across the United States face a critical window of opportunity for clinical trial participation. Over 2,100 trials are slated to close within the next 90 days, meaning time is running out to enroll. This urgent call to action includes 636 studies actively seeking healthy volunteers, offering a chance to contribute to medical science without a specific health condition.

For those with particular health needs, several conditions have a significant number of trials nearing their conclusion. If you or someone you know is living with one of these conditions, now is the time to explore potential enrollment:

• Breast cancer (46 trials closing)
• Healthy (37 trials closing)
• Depression (32 trials closing)
• Cancer (31 trials closing)
• Obesity (26 trials closing)
• Prostate cancer (25 trials closing)
• Stroke (25 trials closing)
• Heart failure (20 trials closing)
• Opioid use disorder (18 trials closing)
• Anxiety (18 trials closing)

Groundbreaking Research Initiatives Launch Nationwide

This month, the nation welcomes 722 new clinical trials, a slight increase from the 714 that opened in May 2026. These new studies include several large-scale initiatives and significant drug trials from major sponsors, offering participants access to cutting-edge research across a wide spectrum of health challenges.

Among the most notable new trials are:

• The "Human Observatory Study" (NCT07646782), sponsored by Longevity Metrics, Inc., is a prospective observational study aiming to enroll 1,000,000 participants. It seeks to build a continuously updating world model for human health, disease, and death by linking individual multi-system clinical data.
• Veterans Recovery Network Inc. is sponsoring "QAIAx (AIhealth4U) - AI Public Health Central: Microcity-A" (NCT07661823), also targeting 1,000,000 participants. This study will test whether an "AI City Hall Project" can provide free or low-cost behavioral and mental health services within self-contained communities.
• Another massive initiative, the "Health Ahead Comparative Effectiveness Study" (NCT07669168), sponsored by William Brandenburg, MD, plans to enroll 1,000,000 participants. This pragmatic study systematically compares changes to preventive health screening on the path toward a fully automated screening system.
• NYU Langone Health is leading "Implementation of Communication Disability Collection and Accommodations in Primary Care Settings" (NCT07656584), a multi-methods-multi-site study aiming for 126,870 participants to adapt and evaluate strategies for documenting patients' communication disability and accommodation needs in electronic health records.
• For those interested in the impact of obesity medications, Indiana University is sponsoring "Estimating the Impact of Obesity Medications on Clinical and Economic Outcomes" (NCT07640139), an observational study with 125,000 participants. It aims to identify the impact of incretin-based obesity medications (like GLP-1 and GLP-1/GIP) on health and economic outcomes.
• Brigham and Women's Hospital is sponsoring two significant comparative effectiveness studies: "Injectable Semaglutide vs Dulaglutide in Individuals at Cardiovascular Risk" (NCT07619495) with 120,000 participants, and "Tirzepatide vs Semaglutide in Individuals at Cardiovascular Risk But Without Diabetes" (NCT07619508) with 100,000 participants. These studies use real-world data to compare the effectiveness of popular GLP-1 agonists.
• Novo Nordisk A/S, a major pharmaceutical sponsor, is leading "Weight Loss in Adults Using Semaglutide (Real-world Study)" (NCT07627074), assessing weight loss in 35,000 participants treated with commercially available semaglutide in routine clinical practice.
• The University of Massachusetts, Worcester, is sponsoring "Patient-Centered Practical Vaccine Talk For Busy Clinicians" (NCT07651761), a pragmatic trial with 24,500 participants to assess the effect of an educational intervention for primary care providers on influenza and COVID-19 vaccine uptake.
• The University of Pennsylvania is launching "Preventive Reminder Ordering AssistanCe Via Texting for Improved Visit Encounters" (NCT07636187) with 16,416 participants, aiming to improve adherence to key preventive health screenings.
• Colgate Palmolive is sponsoring a Phase 4 trial, "Evaluate the Efficacy of an Oral Health Behavioral Intervention in People With Diabetes" (NCT07619729), involving 10,000 participants, to evaluate the effect of a behavioral intervention on dental claims in people with Type 2 Diabetes.

A National View: Where Research is Thriving

The United States currently has 22,174 clinical trials recruiting across 2,746 cities and 43,100 research sites. This month's new trial activity shows a clear concentration in certain states, reflecting established research hubs and large population centers. The states leading in new trial openings are:

• California (134 new trials)
• New York (106 new trials)
• Texas (102 new trials)
• Florida (90 new trials)
• Pennsylvania (62 new trials)
• Ohio (60 new trials)
• Massachusetts (59 new trials)
• Illinois (48 new trials)
• Maryland (47 new trials)
• North Carolina (43 new trials)
• Georgia (41 new trials)
• Missouri (38 new trials)
• Tennessee (37 new trials)
• Michigan (36 new trials)
• Washington (35 new trials)

These figures highlight a strong presence of new research on the East and West Coasts, as well as in major inland states like Texas, Ohio, and Illinois. This distribution means that residents in these leading states often have more immediate access to a wider variety of cutting-edge research opportunities. However, the nationwide scope ensures that trials are accessible in many other states, albeit with fewer new options this month.

Top Cities: Hubs of Innovation

Within these leading states, specific metropolitan areas continue to be hotspots for clinical research. The cities with the highest number of new trials this month are:

• New York, New York (62 new trials)
• Houston, Texas (46 new trials)
• Boston, Massachusetts (37 new trials)
• Chicago, Illinois (34 new trials)
• Los Angeles, California (31 new trials)
• San Antonio, Texas (28 new trials)
• Philadelphia, Pennsylvania (27 new trials)
• Atlanta, Georgia (25 new trials)
• St Louis, Missouri (24 new trials)
• Dallas, Texas (24 new trials)

These urban centers, often home to major academic medical institutions and pharmaceutical company offices, serve as crucial engines for medical advancement. While these cities offer abundant opportunities, individuals in less populated areas may need to consider travel or remote participation options for certain studies.

New Trials by Condition and Intervention Type

The 722 new trials opening this month address a diverse range of health conditions. The most common conditions targeted by these new studies include:

• Breast cancer (15 new trials)
• Prostate cancer (12 new trials)
• Healthy (12 new trials)
• Obesity (11 new trials)
• Stroke (11 new trials)
• Overweight (8 new trials)
• Migraine (7 new trials)
• Anxiety (7 new trials)
• Head and neck cancer (6 new trials)
• Type 2 diabetes (6 new trials)

Drug trials continue to be the most prevalent type of intervention, accounting for 241 of the new studies. Behavioral interventions are also significant with 151 new trials, followed by device studies (128), and procedures (46). This broad spectrum of research types ensures that various approaches to health and disease are being explored.

Opportunities for Healthy Volunteers and Diverse Demographics

For individuals without a specific medical condition, there are substantial opportunities to contribute to medical science. Of the 722 new trials launched this month, 185 are actively seeking healthy volunteers. Nationwide, a total of 5,178 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Clinical trials are designed to be inclusive, with a broad range of eligibility criteria. Of the new trials, 108 include children as participants, 54 are female-only, 24 are male-only, and 572 include older adults. This ensures that research benefits diverse age groups and specific populations. Academic institutions remain vital to the nation's research ecosystem, with the University of California, San Francisco, Mayo Clinic, and Stanford University leading in new trial sponsorships. Industry sponsors like AstraZeneca are also driving significant research efforts, particularly in drug development.

As we move forward, the landscape of clinical research promises continued innovation, with a strong emphasis on large-scale observational studies and the development of new treatments for widespread health challenges. The ongoing efforts to understand and improve human health will rely on the continued participation of dedicated volunteers across the country.